[ET Net News Agency, 24 March 2025] UBS raised the target price for Hansoh Pharma
(03692) to HKD24 from HKD22.1 and maintained the "buy" rating.
The research house said it raises 2025/26E EPS by 11%/9% respectively, to RMB0.67 and
RMB0.75, as per reported financials and updated guidance. (rc)